0 CHECKOUT

Systemic Lupus Erythematosus - Pipeline Review, H2 2015

  • ID: 3429821
  • August 2015
  • 301 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Biogen, Inc.
  • GlaxoSmithKline Plc
  • Kadmon Corporation, LLC
  • Neovacs SA
  • Resolve Therapeutics, LLC
  • MORE

Systemic Lupus Erythematosus - Pipeline Review, H2 2015

Summary

The report ‘Systemic Lupus Erythematosus - Pipeline Review, H2 2015’, provides an overview of the Systemic Lupus Erythematosus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Biogen, Inc.
  • GlaxoSmithKline Plc
  • Kadmon Corporation, LLC
  • Neovacs SA
  • Resolve Therapeutics, LLC
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Systemic Lupus Erythematosus Overview

Therapeutics Development

Pipeline Products for Systemic Lupus Erythematosus - Overview

Pipeline Products for Systemic Lupus Erythematosus - Comparative Analysis

Systemic Lupus Erythematosus - Therapeutics under Development by Companies

Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes

Systemic Lupus Erythematosus - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Systemic Lupus Erythematosus - Products under Development by Companies

Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development

4SC AG

AbbVie Inc.

Ablynx NV

Actelion Ltd

AiCuris GmbH & Co. KG

Amgen Inc.

Anthera Pharmaceuticals‚ Inc.

Argos Therapeutics, Inc.

Biogen, Inc.

Biotest AG

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

Chong Kun Dang Pharmaceutical Corp.

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Genosco

Genovax S.r.l.

GlaxoSmithKline Plc

Hansa Medical AB

ImmuNext, Inc.

Immunomedics, Inc.

Immupharma Plc

Invion Limited

Johnson & Johnson

Kadmon Corporation, LLC

Karyopharm Therapeutics, Inc.

Kineta, Inc.

Lead Discovery Center GmbH

MacroGenics, Inc.

MedAnnex Ltd

MedImmune, LLC

Medsenic

Merck KGaA

Mitsubishi Tanabe Pharma Corporation

Neovacs SA

Nippon Chemiphar Co., Ltd.

Ocata Therapeutics, Inc.

Padlock Therapeutics, Inc.

Pfizer Inc.

Plexxikon Inc.

Principia Biopharma Inc.

RedHill Biopharma Ltd.

Redx Pharma Plc

Resolve Therapeutics, LLC

Sanofi

Sarepta Therapeutics, Inc.

SBI Biotech Co., Ltd.

Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

Therapix Biosciences Ltd

UCB S.A.

Xencor, Inc.

XTL Biopharmaceuticals Ltd.

Systemic Lupus Erythematosus - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(rifabutin + clarithromycin + clofazimine) - Drug Profile

abatacept - Drug Profile

ABBV-084 - Drug Profile

ABS-11 - Drug Profile

ACT-334441 - Drug Profile

AGS-009 - Drug Profile

AIC-284 - Drug Profile

ALX-0061 - Drug Profile

AMG-557 - Drug Profile

AMG-729 - Drug Profile

AMG-811 - Drug Profile

anifrolumab - Drug Profile

Annexuzlimab - Drug Profile

Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus - Drug Profile

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile

arsenic trioxide - Drug Profile

AT-791 - Drug Profile

atacicept - Drug Profile

BB-004 - Drug Profile

belimumab - Drug Profile

BIIB-059 - Drug Profile

blisibimod - Drug Profile

brentuximab vedotin - Drug Profile

BT-063 - Drug Profile

CC-220 - Drug Profile

Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile

CKD-506 - Drug Profile

dalazatide - Drug Profile

dapirolizumab pegol - Drug Profile

Drug to Inhibit PAD for Autoimmune Diseases, CNS and Oncology - Drug Profile

E-6446 - Drug Profile

edratide - Drug Profile

Endoglycosidase of Streptococcus pyogenes - Drug Profile

forigerimod acetate - Drug Profile

GNKS-356 - Drug Profile

GX-101 - Drug Profile

IGM-001 - Drug Profile

IMP-10 - Drug Profile

INV-103 - Drug Profile

JB-6121 - Drug Profile

KD-025 - Drug Profile

KPT-350 - Drug Profile

Leukothera - Drug Profile

lulizumab pegol - Drug Profile

MGD-010 - Drug Profile

milatuzumab - Drug Profile

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile

MT-1303 - Drug Profile

NC-2400 - Drug Profile

NCS-613 - Drug Profile

PF-04236921 - Drug Profile

PRN-1008 - Drug Profile

Recombinant Proteins for Systemic Lupus Erythematosus - Drug Profile

RN-486 - Drug Profile

RO-5461111 - Drug Profile

RSLV-132 - Drug Profile

RSLV-133 - Drug Profile

SAR-113244 - Drug Profile

SBI-3150 - Drug Profile

sifalimumab - Drug Profile

SM-101 - Drug Profile

SM-934 - Drug Profile

Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile

Small Molecule to Inhibit Immunoproteasome Subunit LMP7 for Autoimmune Disorders and Viral Infections - Drug Profile

Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile

Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile

Small Molecule to Inhibit SYK for Systemic Lupus Erythematosus and Rheumatoid Arthritis - Drug Profile

Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases - Drug Profile

Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile

Stem Cell Therapy for Autoimmune Diseases - Drug Profile

Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile

Stem Cell Therapy for Systemic Lupus Erythematosus - Drug Profile

Synthetic Peptide for Systemic Lupus Erythematosus - Drug Profile

Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile

TAK-079 - Drug Profile

TAK-114 - Drug Profile

TAM-01 - Drug Profile

ustekinumab - Drug Profile

Vaccine for Systemic Lupus Erythematosus - Drug Profile

Vaccine to Target Interferon Alpha for Systemic Lupus Erythematosus, Chronic Viral Infections and Dermatomyositis - Drug Profile

venetoclax - Drug Profile

VISTA-Ig - Drug Profile

XmAb-5871 - Drug Profile

Y-27 - Drug Profile

Systemic Lupus Erythematosus - Recent Pipeline Updates

Systemic Lupus Erythematosus - Dormant Projects

Systemic Lupus Erythematosus - Discontinued Products

Systemic Lupus Erythematosus - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2015

Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd..1)

Number of Products under Development by Companies, H2 2015 (Contd..2)

Number of Products under Development by Companies, H2 2015 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Development by Companies, H2 2015 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2015

Systemic Lupus Erythematosus - Pipeline by 4SC AG, H2 2015

Systemic Lupus Erythematosus - Pipeline by AbbVie Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2015

Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H2 2015

Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co. KG, H2 2015

Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals‚ Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Biogen, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2015

Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H2 2015

Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H2 2015

Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015

Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H2 2015

Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Systemic Lupus Erythematosus - Pipeline by Genosco, H2 2015

Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H2 2015

Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2015

Systemic Lupus Erythematosus - Pipeline by Hansa Medical AB, H2 2015

Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2015

Systemic Lupus Erythematosus - Pipeline by Invion Limited, H2 2015

Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2015

Systemic Lupus Erythematosus - Pipeline by Kadmon Corporation, LLC, H2 2015

Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Kineta, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2015

Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2015

Systemic Lupus Erythematosus - Pipeline by MedImmune, LLC, H2 2015

Systemic Lupus Erythematosus - Pipeline by Medsenic, H2 2015

Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2015

Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015

Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2015

Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015

Systemic Lupus Erythematosus - Pipeline by Ocata Therapeutics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Padlock Therapeutics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Pfizer Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Plexxikon Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H2 2015

Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H2 2015

Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H2 2015

Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2015

Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H2 2015

Systemic Lupus Erythematosus - Pipeline by Seattle Genetics, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015

Systemic Lupus Erythematosus - Pipeline by Therapix Biosciences Ltd, H2 2015

Systemic Lupus Erythematosus - Pipeline by UCB S.A., H2 2015

Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H2 2015

Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Systemic Lupus Erythematosus Therapeutics - Recent Pipeline Updates, H2 2015

Systemic Lupus Erythematosus - Dormant Projects, H2 2015

Systemic Lupus Erythematosus - Dormant Projects (Contd..1), H2 2015

Systemic Lupus Erythematosus - Dormant Projects (Contd..2), H2 2015

Systemic Lupus Erythematosus - Dormant Projects (Contd..3), H2 2015

Systemic Lupus Erythematosus - Dormant Projects (Contd..4), H2 2015

Systemic Lupus Erythematosus - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H2 2015

Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Routes of Administration, H2 2015

Number of Products by Stage and Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

4SC AG
AbbVie Inc.
Ablynx NV
Actelion Ltd
AiCuris GmbH & Co. KG
Amgen Inc.
Anthera Pharmaceuticals‚ Inc.
Argos Therapeutics, Inc.
Biogen, Inc.
Biotest AG
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
Chong Kun Dang Pharmaceutical Corp.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Genosco
Genovax S.r.l.
GlaxoSmithKline Plc
Hansa Medical AB
ImmuNext, Inc.
Immunomedics, Inc.
Immupharma Plc
Invion Limited
Johnson & Johnson
Kadmon Corporation, LLC
Karyopharm Therapeutics, Inc.
Kineta, Inc.
Lead Discovery Center GmbH
MacroGenics, Inc.
MedAnnex Ltd
MedImmune, LLC
Medsenic
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Neovacs SA
Nippon Chemiphar Co., Ltd.
Ocata Therapeutics, Inc.
Padlock Therapeutics, Inc.
Pfizer Inc.
Plexxikon Inc.
Principia Biopharma Inc.
RedHill Biopharma Ltd.
Redx Pharma Plc
Resolve Therapeutics, LLC
Sanofi
Sarepta Therapeutics, Inc.
SBI Biotech Co., Ltd.
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Therapix Biosciences Ltd
UCB S.A.
Xencor, Inc.
XTL Biopharmaceuticals Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare